HK1223284A1 - Cysteine or a derivative thereof for the treatment of atrophic gastritis - Google Patents

Cysteine or a derivative thereof for the treatment of atrophic gastritis

Info

Publication number
HK1223284A1
HK1223284A1 HK16111568.1A HK16111568A HK1223284A1 HK 1223284 A1 HK1223284 A1 HK 1223284A1 HK 16111568 A HK16111568 A HK 16111568A HK 1223284 A1 HK1223284 A1 HK 1223284A1
Authority
HK
Hong Kong
Prior art keywords
cysteine
derivative
treatment
atrophic gastritis
atrophic
Prior art date
Application number
HK16111568.1A
Other languages
Chinese (zh)
Inventor
Osmo Suovaniemi
Original Assignee
Biohit Oyj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohit Oyj filed Critical Biohit Oyj
Publication of HK1223284A1 publication Critical patent/HK1223284A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK16111568.1A 2013-05-13 2016-10-05 Cysteine or a derivative thereof for the treatment of atrophic gastritis HK1223284A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20135503A FI20135503L (en) 2013-05-13 2013-05-13 Cysteine or its derivative for the treatment of atrophic gastritis
PCT/FI2014/050351 WO2014184435A1 (en) 2013-05-13 2014-05-12 Cysteine or a derivative thereof for the treatment of atrophic gastritis

Publications (1)

Publication Number Publication Date
HK1223284A1 true HK1223284A1 (en) 2017-07-28

Family

ID=51897812

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16111568.1A HK1223284A1 (en) 2013-05-13 2016-10-05 Cysteine or a derivative thereof for the treatment of atrophic gastritis

Country Status (6)

Country Link
EP (1) EP2996687A4 (en)
CN (1) CN105492002A (en)
EA (1) EA201591994A1 (en)
FI (1) FI20135503L (en)
HK (1) HK1223284A1 (en)
WO (1) WO2014184435A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20216361A1 (en) * 2021-12-29 2023-06-30 Biohit Oyj Use of L-cysteine for improving the structure and function of gastric mucosa

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI122914B (en) * 2005-04-01 2012-08-31 Biohit Oyj Food composition for binding of acetaldehyde in the mouth and in the digestive tract and process for the preparation of the composition
FI20060501L (en) * 2006-05-22 2007-11-23 Biohit Oyj Composition and method for binding acetaldehyde in the stomach
FI20065542A0 (en) * 2006-09-01 2006-09-01 Biohit Oyj Method and Sampling Kit for Assessment of Abdominal Mucosal Condition
WO2009137827A2 (en) * 2008-05-09 2009-11-12 Tiara Pharmaceuticals, Inc. Controlled release of n-acetylcysteine (nac) for reduction of systemic and/or vascular inflammation
FI20115377A (en) * 2011-04-18 2012-10-19 Biohit Oyj Medical products for use in conditions related to microbial infections of upper respiratory and digestive organs
WO2014140411A1 (en) * 2013-03-12 2014-09-18 Biohit Oyj Encapsulated composition for binding aldehydes in the stomach

Also Published As

Publication number Publication date
WO2014184435A1 (en) 2014-11-20
EA201591994A1 (en) 2016-05-31
EP2996687A4 (en) 2016-12-07
FI20135503L (en) 2014-11-14
CN105492002A (en) 2016-04-13
EP2996687A1 (en) 2016-03-23

Similar Documents

Publication Publication Date Title
HRP20181679T1 (en) Amide compounds for the treatment of hiv
HK1222994A1 (en) Tobacco treatment
EP2948450A4 (en) Metalloenzyme inhibitor compounds
EP2970627A4 (en) Polymer-graphene nanocomposites
HK1249137A1 (en) Cystathionine beta-synthase enzyme for treatment of homocystinuria
HK1224324A1 (en) Treatment of coal
GB201304872D0 (en) Treatment
HK1214093A1 (en) Tobacco treatment
AP2016009136A0 (en) A method for the treatment of metals
HK1216391A1 (en) Combination treatment
HK1223284A1 (en) Cysteine or a derivative thereof for the treatment of atrophic gastritis
GB2517280B (en) Coffin
GB201307310D0 (en) Treatment
ZA201404930B (en) Plant treatment composition
GB201301407D0 (en) 17 Deemed-Ties Blackjack
GB201311468D0 (en) Packing 17
GB201321115D0 (en) Treatment
GB201320653D0 (en) Treatment of plants
GB201309238D0 (en) Treatment